-
1.发明公开Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same 审中-公开为了抑制生长因子受体能够Hepazotyten喹啉和喹唑啉衍生物和含有它们的药物组合物的自磷酸化
公开(公告)号：EP2088141A3
公开(公告)日：2009-11-18
申请号：EP09160115.3
申请日：2002-06-21
发明人： Fujiwara, Yasunari , Senga, Terufumi , Nishitoba, Tsuyoshi , Osawa, Tatsushi , Miwa, Atsushi , Nakamura, Kazuhide
IPC分类号： C07D215/22 , C07D239/86 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/517 , A61K31/5377 , A61P35/00
CPC分类号： C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/517 , A61K31/5377 , C07D215/40 , C07D239/88 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein X = CH or N; Z = O or S; L = O or S; M = CR 10 R 11 , wherein R 10 and E 11 = H, alkyl, or alkoxy, NR 12 wherein R 12 = H or alkyl; R 1 , R 2 , and R 3 = H or optionally substituted alkoxy; R 4 = H; R 5-8 = H, halogen, alkoxy or the like; and R 9 = alkyl optionally substituted by -R 14 , -T-R 15 , or -NR 16 R 17 wherein T = O, S, or NH; R 14 = an optionally substituted carbocyclic or heterocyclic ring; and R 15-17 = alkyl or an optionally substituted carbocyclic or heterocyclic ring, or -NR 18 R 19 wherein R 18 and R 19 = H, optionally substituted alkyl, or an optionally substituted carbocyclic or heterocyclic ring, or optionally substituted carbocyclic or heterocyclic ring.-
公开(公告)号：EP2022855A1
公开(公告)日：2009-02-11
申请号：EP07743912.3
申请日：2007-05-16
发明人： CHIBA, Yasunori , JIGAMI, Yoshifumi , KURODA, Kosuke , KOBAYASHI, Kazuo , ICHIKAWA, Kimihisa , NONAKA, Koichi , SUZUKI, Takeshi
CPC分类号： C07K16/2875 , C07K16/00
摘要： This invention provides a means for enabling high-level secretory production of proteins, in particular proteins having complicated structures such as antibodies, in host cells such as yeast cells. The invention also provides transformed yeast cells having the activated HAC1 gene and the RRBP1 gene and a method for enabling high-level secretory production of foreign proteins using such transformed host cells by inhibiting O-sugar chain formation indigenous to host cells such as yeast cells.
摘要翻译： 本发明提供了用于在宿主细胞如酵母细胞中高水平分泌性生产蛋白质，特别是具有复杂结构如抗体的蛋白质的手段。 本发明还提供具有活化的HAC1基因和RRBP1基因的转化酵母细胞，以及通过抑制宿主细胞如酵母细胞固有的O-糖链形成，使用这种转化的宿主细胞能够高水平分泌生产外源蛋白质的方法。
-
公开(公告)号：EP1505149B1
公开(公告)日：2009-01-07
申请号：EP03720967.3
申请日：2003-04-28
申请人： Kirin Pharma Kabushiki Kaisha , National Institute of Advanced Industrial Science and Technology
发明人： KOBAYASHI, Kazuo, Kirin Beer Kabushiki Kaisha , KITAGAWA, Yoshinori, Kirin Beer Kabushiki Kaisha , KOMEDA, Toshihiro, Kirin Beer Kabushiki Kaisha , KAWASHIMA, Nagako, Kirin Beer Kabushiki Kaisha , JIGAMI, Y., Nat. Inst. of Adv. Ind. Scie. Tech. , CHIBA, Y., Nat. Inst. of. Adv. Ind. Scie. Tech.
CPC分类号： C12P19/26 , C07K16/243 , C07K2317/21 , C12N1/14 , C12N9/0006 , C12N9/0008 , C12N9/1048 , C12N9/1051 , C12N9/2488 , C12N9/60 , C12N9/88 , C12N9/93 , C12P21/02 , C12Y101/01085 , C12Y101/03013 , C12Y102/01012 , C12Y302/01024 , C12Y402/01019 , C12Y603/02006
摘要： It is intended to provide a process for producing a glycoprotein having a mammalian type sugar chain characterized by comprising transferring and expressing α-1,2-mannosidase in a sugar chain biosynthesis pathway gene mutant of a methylotroph yeast under the control by a potent promoter, culturing in a medium the methylotroph yeast cells having a foreign gene transferred thereinto, and then harvesting the glycoprotein having the mammalian type sugar chain from the culture medium. Using a newly bred methylotroph yeast carrying a sugar chain mutation, a neutral sugar chain identical with a high mannose type sugar chain produced by mammalian cells such as human cells or a glycoprotein having such a neutral sugar chain can be produced in a large amount at a high purity. By transferring a gene in a mammalian type sugar chain biosynthesis pathway into the above-described mutant, a mammalian type sugar chain such as a hybrid sugar chain or a complex sugar chain or a protein having a mammalian type sugar chain can be efficiently produced.
-
公开(公告)号：EP2009027A1
公开(公告)日：2008-12-31
申请号：EP08017499.8
申请日：2002-04-26
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2319/00 , C07K2319/30
摘要： An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
摘要翻译： 一种抗体或其功能片段，在CD40上起激动作用或拮抗作用。
-
5.发明公开AGONISTIC ANTIBODY DIRECTED AGAINST HUMAN THROMBOPOIETIN RECEPTOR 审中-公开GEGEN MENSCHLICHEN THROMBOPOETIN-REZEPTOR GERICHTETER AGONISTISCHERANTIKÖRPER
公开(公告)号：EP2006380A1
公开(公告)日：2008-12-24
申请号：EP07739974.9
申请日：2007-03-20
发明人： KAI, Masayuki, c/o Kirin Pharma K.K. , MOTOKI, Kazuhiro, c/o Kirin Pharma K.K. , KATAOKA, Shiro, c/o Kirin Pharma K.K. , YOSHIDA, Hideaki, c/o Kirin Pharma K.K. , HAGIWARA, Tetsuya, c/o Kirin Pharma K.K.
IPC分类号： C12N15/09 , A61K39/395 , A61P7/00 , A61P7/04 , A61P43/00 , C07K16/28 , C07K16/46 , C12N15/02 , C12P21/08
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/524 , C07K14/715 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/72 , C07K2317/74 , Y10S424/801 , Y10S424/809
摘要： This invention provides an agonist antibody to a human thrombopoietin receptor (alias: human c-Mpl). More particularly, this invention provides an agonist antibody to a human thrombopoietin receptor, wherein the agonist antibody comprises: antibody constant regions comprising (1) amino acid sequences in a heavy chain constant region and a light chain constant region of a human antibody, (2) an amino acid sequence of a heavy chain constant region with a domain substituted between human antibody subclasses, and an amino acid sequence of a light chain constant region of a human antibody, or (3) amino acid sequences comprising a deletion(s), substitution(s), addition(s), or insertion(s) of one or several amino acid residues in the amino acid sequences of (1) or (2) above ; and antibody variable regions capable of binding to and activating a human thrombopoietin receptor; and wherein the agonist antibody has the properties: (a) that the antibody induces colony formation at a concentration of 10,000 ng/ml or lower as determined by the CFU-MK colony formation assay using human umbilical-cord-blood-derived CD34+ cells; and (b) that the antibody has a maximal activity at least 50% higher than that of PEG-rHuMGDF and an 50% effective concentration (EC50) of 100 nM or less in the cell proliferation assay using UT7/TPO cell. Also provided is a pharmaceutical composition for treating thrombocytopenia comprising said antibody.
摘要翻译： 本发明提供了对人血小板生成素受体（别名：人c-Mpl）的激动剂抗体。 更具体地说，本发明提供对人血小板生成素受体的激动剂抗体，其中所述激动剂抗体包含：抗体恒定区，其包含（1）重链恒定区中的氨基酸序列和人抗体的轻链恒定区，（2 ）具有在人抗体亚类和人抗体的轻链恒定区的氨基酸序列之间取代的结构域的重链恒定区的氨基酸序列，或（3）包含缺失的氨基酸序列， 上述（1）或（2）的氨基酸序列中一个或几个氨基酸残基的取代，添加或插入; 和能够结合并激活人类血小板生成素受体的抗体可变区; 并且其中所述激动剂抗体具有以下性质：（a）所述抗体通过使用人脐带血衍生的CD34 +细胞的CFU-MK集落形成测定法测定，浓度为10,000ng / ml或更低的浓度形成; 和（b）在使用UT7 / TPO细胞的细胞增殖测定中，抗体具有比PEG-rHuMGDF高至少50％的最大活性和100nM或更低的50％有效浓度（EC 50）。 还提供了用于治疗血小板减少症的药物组合物，其包含所述抗体。
-
公开(公告)号：EP2003969A2
公开(公告)日：2008-12-24
申请号：EP07755113.3
申请日：2007-04-06
CPC分类号： C12N5/0639 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , C12N2501/24 , C12N2501/52 , C12N2510/00
摘要： This invention provides novel CD40L polypeptides and nucleic acids, as well as antigen presenting cells and vaccines comprising such CD40L polypeptides and/or nucleic acids, and related methods for preparing the antigen presenting cells and vaccines. The antigen presenting cells and vaccines are useful for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g., mRNA or DNA), an agonistic antibody to CD40 receptor or by CD40 ligand polypeptide. The enriched populations can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen on its cell surface.
-
7.发明公开DEVICES, SYSTEMS AND RELATED METHODS SUITABLE FOR DELIVERY OF A LIQUID MEDICAMENT STORED AT CRYOGENIC TEMPERATURES 审中-公开设备，系统和发出超低温相关方法在液体储存的药物
公开(公告)号：EP1933930A2
公开(公告)日：2008-06-25
申请号：EP06826082.7
申请日：2006-10-13
发明人： GRANT, Richard, Alexander , LEIGH-LANCASTER, Christopher, John , ZIPSIN, Andrew , PEELE, Timothy, Doyle , FITZPATRICK, Ian, S.
IPC分类号： A61M37/00
CPC分类号： A61M5/2425 , A61J1/201 , A61J1/2013 , A61J1/2017 , A61J1/2051 , A61J1/2065 , A61J1/2096 , A61M5/001 , A61M5/2053 , A61M5/2466 , A61M5/31555 , A61M5/3158 , A61M5/44 , A61M2005/2474 , A61M2005/3128 , A61M2205/3368 , A61M2205/3653
摘要： Medicament devices include a sealed medicament dose container comprising a cell based medicament that is stored at a temperature less than about -40 degrees Celsius, then thawed into a liquid prior to administration and a medicament dose cartridge configured and sized to snugly hold the dose container therein during extraction of the liquid medicament. Related dose containers, retainers and extraction/dispensing systems are also described.
-
公开(公告)号：EP1914243A3
公开(公告)日：2008-06-18
申请号：EP07014664.2
申请日：2002-04-26
发明人： Mikayama, Toshifumi, Pharmaceutical Research Laboratories, Kirin Beer K.K. , Yoshida, Hitoshi c/o Kirin Pharma company, Ltd. , Force, Walker R c/o Kirin Pharma, USA, Inc. , Chen, Xingjie , Takahashi, Nobuaki, Pharmaceutical Research Laboratories, Kirin Beer K.K.
IPC分类号： C07K16/28 , C12N15/13 , C12N5/10 , C12P21/08 , A61K39/395 , A61P35/00 , A61P37/04 , A61P37/06 , A61P37/08 , A61P7/00
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
摘要翻译： 激动或拮抗CD40的抗体或其功能片段。
-
9.发明公开THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING C-MET AUTOPHOSPHORYLATION INHIBITING POTENCY 审中-公开三烯酰胆碱衍生物中性粒细胞中华大鼠麻醉药自身免疫疗法维生素C维生素WIRKUNG
公开(公告)号：EP1870414A1
公开(公告)日：2007-12-26
申请号：EP06730282.8
申请日：2006-03-28
发明人： KUBO, Kazuo c/o Discovery Research Laboratories , FURUTA, Takayuki c/o Discovery Research Laboratories , OSAWA, Tatsushi c/o Discovery Research Laboratories , MIWA, Atsushi c/o Discovery Research Laboratories
IPC分类号： C07D495/04 , A61K31/4365 , A61K31/4709 , A61P35/00 , A61P43/00 , C07D401/12 , C07D471/04
CPC分类号： C07D495/04 , C07D401/12 , C07D471/04
摘要： An objective of the present invention is to provide compounds having antitumor activity. According to the present invention, there is provided compounds represented by formula (I) and pharmaceutically acceptable salts thereof, and solvates thereof:
wherein R 1 represents H or a substitutable unsaturated five- or six-membered heterocyclic ring; R 2 represents H; X represents CH or N; Z represents O or S; E is absent or represents halogen, alkyl, or alkoxy; J represents S or O; and T represents phenyl, an unsaturated five- or six-membered heterocyclic ring, an unsaturated nine- or ten-membered bicyclic carbocyclic ring or heterocyclic ring.摘要翻译： 本发明的目的是提供具有抗肿瘤活性的化合物。 根据本发明，提供了式（I）表示的化合物及其药学上可接受的盐及其溶剂合物：其中R 1表示H或可取代的不饱和五元或六元杂环; R 2表示H; X表示CH或N; Z表示O或S; E不存在或表示卤素，烷基或烷氧基; J表示S或O; T代表苯基，不饱和五元或六元杂环，不饱和九元或十元双环碳环或杂环。
-
10.发明授权Quinoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same 有权为了抑制生长因子受体能够Hepazotyten喹啉衍生物和含有它们的药物组合物的自磷酸化
公开(公告)号：EP2258366B1
公开(公告)日：2013-04-03
申请号：EP10179308.1
申请日：2002-06-21
发明人： Fujiwara, Yasunari , Senga, Terufumi , Nishitoba, Tsuyoshi , Osawa, Tatsushi , Miwa, Atsushi , Nakamura, Kazuhide
IPC分类号： A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/517 , A61K31/5377 , A61P35/00 , C07D215/40 , C07D239/88 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D215/233
CPC分类号： C07D215/233 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/517 , A61K31/5377 , C07D215/40 , C07D239/88 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.033 秒)
